Drug Dependence Clinical Trial
Official title:
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
Background:
- The therapeutic alliance between therapist and patient may contribute to favorable
outcomes in all types of psychotherapy, including cognitive behavioral therapy (CBT) for
drug dependence. Oxytocin, a hormone and neurotransmitter, has been shown to increase trust
in other people and may reduce stress and improve comfort in social situations by decreasing
the sensation of social anxiety. Researchers are interested in determining if oxytocin can
improve the outcomes of therapy for drug dependence by strengthening perceived levels of
trust between therapist and patient.
Objectives:
- To determine whether oxytocin enhances the therapeutic alliance and treatment retention
for CBT for drug use.
Eligibility:
- Individuals between 18 and 65 years of age who are healthy volunteers with no history of
drug abuse, participants in outpatient or inpatient treatment programs for cocaine use,
methadone-dependent participants in a treatment program, or non-treatment-seeking cocaine
users.
Design:
- Participants in each treatment arm who comply with the study requirements will be
randomly assigned to receive one dose of oxytocin or placebo approximately 1 hour
before each weekly CBT session.
- The outpatient treatment intervention will be 12 weeks of weekly individual CBT. The
inpatient treatment intervention will be 6 weeks of twice-weekly individual CBT
sessions. Sessions will be audiotaped. Participants and counselors will be told that
the sessions are to be taped.
- During treatment, participants will provide urine and breath samples under staff
observation. Participants will also complete questionnaires about mood and mental
health, provide other samples as required, and participate in computerized
psychological testing as directed by researchers.
Objective The therapeutic alliance (TA), a working relationship between therapist and
patient, may contribute to favorable outcomes in all types of psychotherapy, including
cognitive-behavioral therapy (CBT) for drug dependence. Enhancement of the TA may be
possible through intranasal administration of the hormone and neurotransmitter oxytocin,
which is associated with social bonding and trust. The objective of this study is to
determine whether addition of intranasal oxytocin to a course of CBT for drug dependence
enhances TA and treatment retention and reduces drug use post-treatment. The study will
assess changes in performance on tasks that probe decision-making, emotional processing, and
drug-cue reactivity. We will employ fMRI on a subset of participants to study the neural
correlates of these processes.
Study population. The treatment portion of the study will be conducted in three parallel
arms, not intended to be statistically compared to each other: (1) Outpatient Methadone arm
(physically dependent heroin users, n = 80 evaluable); (2) Outpatient Cocaine arm
(cocaine-dependent individuals, non-opiate-dependent, n = 80 evaluable); 3) Inpatient
Cocaine arm (cocaine-dependent individuals, non-opiate-dependent, n = 80 evaluable). There
will also be two groups of non-treatment-seeking controls (20 cocaine-using, 20
non-drug-using) to rule out practice effects on tasks; controls will not receive oxytocin or
CBT.
Experimental design and methods. Primary outcome measures will be TA in all arms and drug
use for methadone and cocaine outpatient arms. (1) Methadone arm: after a 5-week baseline
for stabilization on methadone, participants will undergo 12 weeks of CBT, with random
assignment to oxytocin (24 IU, administered before each session) or placebo. (2 and 3)
Cocaine arms, inpatient and outpatient: after a 1-week baseline for assessment of drug use,
participants will undergo 6 and 12 weeks respectively of CBT, with random assignment to
oxytocin (24 IU, administered before each session) or placebo.
Outcome measures: Principle outcome measures for the outpatient arms will be TA measured at
several points during CBT, treatment retention, and attendance at CBT sessions. Secondary
outcome measures are drug use during treatment and at follow-up, drug craving during
treatment and at follow-up, stress reduction during treatment and at follow-up, HIV risk
behaviors during treatment and at follow-up, behavioral performance on various tasks, and
neural response to these tasks for the imaging subgroup. The outcome measures for the
inpatient arm will be the same as for the outpatient arms with the exception of drug use
during treatment.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT00593463 -
Drug Discrimination in Methadone-Maintained Humans Study 1
|
Phase 1 | |
Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01449981 -
Development and Testing of Adolescent Twelve-Step Facilitation
|
N/A | |
Completed |
NCT00183118 -
Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)
|
Phase 1/Phase 2 | |
Completed |
NCT00047866 -
Brain Function in Response to Motivational Stimuli
|
N/A | |
Recruiting |
NCT03333460 -
Transcranial Magnetic Stimulation for Cocaine Addiction
|
N/A | |
Completed |
NCT02124980 -
Automated Recovery Line for Medication Assisted Treatment
|
N/A | |
Completed |
NCT00265512 -
LINK: Aftercare Monitoring Project
|
N/A | |
Completed |
NCT00706901 -
Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Withdrawn |
NCT00675532 -
Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).
|
N/A | |
Active, not recruiting |
NCT03539575 -
CB1R in Synthetic Psychoactive Cannabinoids
|
N/A | |
Completed |
NCT01246401 -
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
|
Phase 1/Phase 2 | |
Completed |
NCT01096550 -
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
|
N/A | |
Completed |
NCT00605033 -
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
|
Phase 4 |